Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent bone problems — such as fractures, spinal cord compressions, and the need for radiation or surgery — in people with multiple myeloma and in those with bone metastases from solid tumors. Xgeva was previously approved in China to treat adults, and adolescents with a mature skeleton, who have giant cell tumor of the bone that is untreatable with surgery. Developed by Amgen,…
You must be logged in to read/download the full post.
The post China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers appeared first on BioNewsFeeds.